top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


From Engineers to AI Experts: The Changing Talent Needs of MedTech
My work has spanned the medical device and diagnostics sectors, supporting senior leaders across Europe and global programmes. Assignments have included work with Software Directors, Affiliate General Managers, Heads of Division, Global Programme and Asset Management leaders, and Chief Operating Officers. The therapeutic areas covered include heart failure, hepatology, and wound management. This breadth has given me exposure to both regional and global perspectives across a r
sharonshieldsconsu
7 days ago3 min read


Q3 MedTech Earnings: Procedure-Driven Growth Meets Capital-Spending Pressure
Q3 2026 medtech results showed a widening gap between fast-growing innovators and companies facing pressure in key product lines. Abbott led among larger players, while Profound Medical and IRadimed posted strong growth from smaller bases. MiMedx and Dentsply Sirona struggled with revenue declines, highlighting how product mix and demand can shape performance across the sector.
sharonshieldsconsu
Nov 123 min read


Integrating Teams After M&A or Strategic Partnerships
Value is driven by what happens bringing together individuals and teams In life sciences, mergers, carve‑outs and strategic alliances are now core to how pipelines advance and products reach patients. But while the deal thesis is usually about science, assets and markets, value is delivered (or destroyed) by what happens with people and ways of working in the first 12–18 months. This year has seen so many significant acquisition, across biotech and medtech, a few of the most
sharonshieldsconsu
Nov 126 min read


Q3 Pharma Earnings: Portfolio Renewal, Therapeutic-Area Concentration, and the Shift to Innovation-Led Growth
Q3 pharmaceutical results highlight a sector moving beyond pandemic-driven revenues toward innovation-led growth. Demand for obesity and specialty medicines is driving strong performance for companies with differentiated products, while mature and COVID-related portfolios continue to face pressure. Acquisitions and portfolio renewal are reshaping growth prospects, even as one-off costs can obscure underlying performance.
For life sciences leaders, this shift has implications
sharonshieldsconsu
Nov 95 min read
bottom of page